[Congressional Record Volume 163, Number 169 (Thursday, October 19, 2017)]
[Senate]
[Page S6673]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1474. Mr. BLUMENTHAL submitted an amendment intended to be 
proposed to amendment SA 1116 proposed by Mr. Enzi to the concurrent 
resolution H. Con. Res. 71, establishing the congressional budget for 
the United States Government for fiscal year 2018 and setting forth the 
appropriate budgetary levels for fiscal years 2019 through 2027; which 
was ordered to lie on the table; as follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO IMPROVING 
                   DRUG PRICING TRANSPARENCY FOR CONSUMERS.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     improving drug pricing transparency for consumers, by the 
     amounts provided in such legislation for those purposes, 
     provided that such legislation would not increase the deficit 
     over either the period of the total of fiscal years 2018 
     through 2022 or the period of the total of fiscal years 2018 
     through 2027.
                                 ______